BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rocha CRR, Reily Rocha A, Molina Silva M, Rodrigues Gomes L, Teatin Latancia M, Andrade Tomaz M, de Souza I, Karolynne Seregni Monteiro L, Menck CFM. Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries. Cells 2020;9:E2573. [PMID: 33271924 DOI: 10.3390/cells9122573] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Awuah WA, Toufik AR, Yarlagadda R, Mikhailova T, Mehta A, Huang H, Kundu M, Lopes L, Benson S, Mykola L, Vladyslav S, Alexiou A, Alghamdi BS, Hashem AM, Md Ashraf G. Exploring the role of Nrf2 signaling in glioblastoma multiforme. Discov Oncol 2022;13:94. [PMID: 36169772 DOI: 10.1007/s12672-022-00556-4] [Reference Citation Analysis]
2 de Souza I, Monteiro LKS, Guedes CB, Silva MM, Andrade-tomaz M, Contieri B, Latancia MT, Mendes D, Porchia BFMM, Lazarini M, Gomes LR, Rocha CRR. High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation. Cell Death Dis 2022;13:591. [DOI: 10.1038/s41419-022-05044-9] [Reference Citation Analysis]
3 de Souza I, Ramalho MCC, Guedes CB, Osawa IYA, Monteiro LKS, Gomes LR, Rocha CRR. Ferroptosis Modulation: Potential Therapeutic Target for Glioblastoma Treatment. IJMS 2022;23:6879. [DOI: 10.3390/ijms23136879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Latancia MT, Moreno NC, Leandro GS, Ribeiro VC, de Souza I, Vieira WKM, Bastos AU, Hoch NC, Rocha CRR, Menck CFM. DNA polymerase eta protects human cells against DNA damage induced by the tumor chemotherapeutic temozolomide. Mutat Res Genet Toxicol Environ Mutagen 2022;878:503498. [PMID: 35649682 DOI: 10.1016/j.mrgentox.2022.503498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Vilar JB, Christmann M, Tomicic MT. Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go? Cancers 2022;14:2416. [DOI: 10.3390/cancers14102416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Codrici E, Popescu ID, Tanase C, Enciu AM. Friends with Benefits: Chemokines, Glioblastoma-Associated Microglia/Macrophages, and Tumor Microenvironment. Int J Mol Sci 2022;23:2509. [PMID: 35269652 DOI: 10.3390/ijms23052509] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
7 Paskeh MDA, Mehrabi A, Gholami MH, Zabolian A, Ranjbar E, Saleki H, Ranjbar A, Hashemi M, Ertas YN, Hushmandi K, Mirzaei S, Ashrafizadeh M, Zarrabi A, Samarghandian S. EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects. Biomed Pharmacother 2021;146:112532. [PMID: 34906772 DOI: 10.1016/j.biopha.2021.112532] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
8 Mazarei M, Mohammadi Arvejeh P, Mozafari MR, Khosravian P, Ghasemi S. Anticancer Potential of Temozolomide-Loaded Eudragit-Chitosan Coated Selenium Nanoparticles: In Vitro Evaluation of Cytotoxicity, Apoptosis and Gene Regulation. Nanomaterials (Basel) 2021;11:1704. [PMID: 34209471 DOI: 10.3390/nano11071704] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Sun X, Turcan S. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. Cells 2021;10:1225. [PMID: 34067729 DOI: 10.3390/cells10051225] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
10 Schirrmacher V. Less Can Be More: The Hormesis Theory of Stress Adaptation in the Global Biosphere and Its Implications. Biomedicines 2021;9:293. [PMID: 33805626 DOI: 10.3390/biomedicines9030293] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 27.0] [Reference Citation Analysis]